ScreenCell® logo
Quote

MB Kit

ScreenCell MB kit
Learn more
Request a quote

So many reasons to use the MB kit in your projects.

4 applications in molecular biology and cell culture.
The MB kit is CE certified and designed for routine clinical use.
A recovery rate greater than 90%.
Allows filtering up to 18 ml of whole blood.
Sample expiration date:
4 hours after collection.
Working on living circulating tumor cells in suspension.

Because numbers worth more than words

Features of the MB kit

Discover a range of applications at your disposal

DNA Extraction

RNA Extraction

Single Cell Sequencing

2D cell culture

3D cell culture

Our application notes using MB kit

Explore our collection of application notes made with the MB kit, offering unique and enriching results.

Learn more
Liquid biopsy technology

A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.

Liquid biopsies represent a valid alternative to conventional tissue biopsies, offering a real time molecular picture of tumors in a...
Bladder cancer

The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer

Simple Summary: Bladder cancer with similar diagnosis based on traditional classification exhibits different behaviors and therapeutic outcomes. Thus, circulating tumor...
Prostate cancer

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer...
Colorectal cancer

Détection des mutations RAS dans les cellules tumorales circulantes : applications au cancer colorectal et perspectives

Les mutations somatiques présentes dans les gènes RAS (KRAS et NRAS) sont largement associées à l’absence de réponse aux traitements...
Breast cancer

Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology

A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the...
Colorectal cancer

Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery

In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab....
Proof of concept

A new device for rapid isolation by size and characterization of rare circulating tumor cells

Background: Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be used for...
Liquid biopsy technology

A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.

Liquid biopsies represent a valid alternative to conventional tissue biopsies, offering a real time molecular picture of tumors in a...
Bladder cancer

The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer

Simple Summary: Bladder cancer with similar diagnosis based on traditional classification exhibits different behaviors and therapeutic outcomes. Thus, circulating tumor...
Prostate cancer

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer...
Colorectal cancer

Détection des mutations RAS dans les cellules tumorales circulantes : applications au cancer colorectal et perspectives

Les mutations somatiques présentes dans les gènes RAS (KRAS et NRAS) sont largement associées à l’absence de réponse aux traitements...
Breast cancer

Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology

A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the...
Colorectal cancer

Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery

In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab....
Proof of concept

A new device for rapid isolation by size and characterization of rare circulating tumor cells

Background: Circulating tumor cells (CTCs) likely derive from clones in the primary tumor, suggesting that they can be used for...
MB Kit

The writings remain,
the words fly away

Immerse yourself in the scientific articles written by our customers and partners, who have used the CYTO kit in their research and testify to its effectiveness.

Lung cancer

An assessment of diagnostic performance of a filter-based antibody-independent peripheral blood circulating tumour cell capture paired with cytomorphologic criteria for the diagnosis of cancer

Objectives Circulating tumour cells (CTCs) are reported to be predictive for prognosis and response to treatment in advanced lung cancer....
Esophageal adenocarcinoma

Cancer-associated Macrophage-like Cells in Patients with Non-metastatic Adenocarcinoma of the Esophagus – Cytomorphological Heterogeneity

Introduction: Esophageal adenocarcinoma (EAC) often recurs systemically despite therapy with a curative aim. New diagnostic and therapeutic approaches are urgently...
Bladder cancer

Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCell™ technology: Potential as a simple cytology test

Circulating tumor cells (CTC) are a recent technique which is a potentially important prognostic factor in many solid tumors. There...
See more articles

Liquid biopsy for
enhancing patient care
through reliable CTC analysis

Get a quote
Request the brochure
ScreenCell MB kit

MB kit features and performance.

Abilities

0 ml

The MB kit can filter up to 18 ml of whole blood.

Performances

+ 0 %

The MB kit has a high coverage rate of over 90%.

Filtration delay

0 hours

CTC capture should be performed within 4 hours of blood collection.